** Drug developer Entrada Therapeutics' TRDA.O shares rise 2.5% to $10.75
** Company says it has received authorization from UK's regulatory agency to begin an early-stage study for an experimental drug, ENTR-601-45, for potential treatment of Duchenne muscular dystrophy, a type of muscle-wasting disorder
** Entrada says it is on track to start study in Q3 2025
** Company's shares have fallen 22.5% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.